The advent of
anti-VEGF drugs aimed at preventing the growth of new blood vessels dramatically changed the prognosis for many patients with the disease.
Various dosing regimens of Zimura were administered in combination with Lucentis in patients with wet AMD who have not been previously treated with
anti-VEGF drugs.
Various dosing regimens of Zimura were administered in combination with Lucentis in patients with wet AMD who have not been previously treated with
anti-VEGF drugs. Based on a preliminary analysis of the safety data from this trial, Zimura combination therapy was generally well tolerated after six months of treatment.
In recent years, several reports have demonstrated the impact of
anti-VEGF drugs upon different cell cultures in vitro.
Previous studies have reported that inhibition of VEGF with
anti-VEGF drugs could reduce retinal permeability and neovascularization [8, 9].
Costagliola, "Pharmacokinetic and pharmacodynamic properties of
anti-VEGF drugs after intravitreal injection," Current Drug Metabolism, vol.
Since the recognition of the role of inflammation and importance of the vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic retinopathy, treatment options have been altered with
anti-VEGF drugs, and corticosteroids have taken an active role in the treatment of diabetic retinopathy [4-7].
Fortunately, the licensing of intravitreal
anti-VEGF drugs (Lucentis and Eylea) for the management of nAMD has revolutionised treatment strategies over the past decade.
The compound that enables delivery of the
anti-VEGF drugs is a cell-penetrating peptide (CPP), which potentially could be used to deliver medications for other ocular diseases that need to be applied to the posterior chamber of the eye.
Despite the benefits of intravitreal
anti-VEGF drugs, interest in the use of oral drug candidates has been increasing [15-17].
However, frequent anti-VEGF injections are prohibitive for most patients because of the high costs of the
anti-VEGF drugs.
This study was to establish a rat retinal edema model and explore the related VEGF expression and observe the responses to
anti-VEGF drugs in this model.
